BIOMARKER FOR OUTCOME PROGNOSIS OF LENALIDOMIDE AND DEXAMETHASONE THERAPY IN MULTIPLE-MYELOMA PATIENTS

摘要

The present invention relates to a biomarker for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, and, more specifically, provides: a biomarker for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients; a composition for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, which comprises a primer or probe that specifically binds to the biomarker; a kit for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, which comprises a primer or probe that specifically binds to the biomarker; a method for providing information on outcome prediction of lenalidomide and dexamethasone therapy; and a method for outcome prediction and treatment of lenalidomide and dexamethasone therapy.